-+ 0.00%
-+ 0.00%
-+ 0.00%

Halozyme Therapeutics Announces Johnson & Johnson Gets FDA Approval For TECVAYLI In Combination With DARZALEX FASPRO To Treat Adults With Relapsed Or Refractory Multiple Myeloma

Benzinga·03/06/2026 13:01:20
Listen to the news

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI® (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy.